Longeveron Jumps 32% on $17.5M Public Offering to Advance Stem Cell Therapy
Longeveron Inc. (LGVN) climbed 31.61% to lead the PRISM Emerging Global Health Index after closing a public offering of up to $17.5 million in gross proceeds. The deal included $5 million upfront through the sale of Class A common stock and short-term warrants, with the potential for an additional $12.5 million if all warrants are exercised. Proceeds will fund clinical and regulatory development of the company’s allogeneic mesenchymal stem cell therapy, laromestrocel (Lomecel-B™), targeting conditions such as hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Multiple FDA designations, including Orphan Drug and RMAT, underscore the therapy’s potential across a range of indications.
Tilray Brands Gains 17% on U.S. Cannabis Reclassification Hopes
Tilray Brands, Inc. (TLRY) continues its climb this week rising 16.78% today, boosting the PRISM Emerging Cannabis Index, following a Wall St. Journal report that President Donald Trump indicated his administration is considering reclassifying cannabis as a less dangerous substance. The announcement, which could come in the next few weeks, sent cannabis stocks sharply higher this week. Investors see reclassification as a major catalyst for industry growth, reducing legal and banking hurdles while broadening institutional participation.
Other PRISM Mid-Day Movers:
• Bit Digital, Inc. (BTCM) up 28.18%
• 180 Life Sciences Corp. (ATNF) up 24.64%
• electroCore, Inc. (ECOR) gained 22.87%
The post PRISM Mid-Day Movers: Regenerative Medicine Financing and Cannabis Policy Momentum Boost Indices appeared first on PRISM MarketView.
